Gregory Madison
Vorstandsvorsitzender bei SHIELD THERAPEUTICS PLC
Vermögen: 31 992 $ am 30.04.2024
Profil
Gregory Paul Madison is currently the Group Chief Executive Officer & Director at Shield Therapeutics Plc.
He is also a Director at Kidney Care Partners, Director at Phosphate Therapeutics Ltd., and a Trustee at American Kidney Fund, Inc. Previously, he served as the President, Chief Executive Officer & Director at Keryx Biopharmaceuticals, Inc. from 2015 to 2018.
He was also the President, Chief Executive Officer & Director at Melt Pharmaceuticals, Inc. Additionally, he worked as the Vice President & General Manager-Nephrology at Genzyme Corp.
from 2000 to 2012 and as the Chief Commercial Officer & Executive VP at AMAG Pharmaceuticals, Inc. from 2013 to 2014.
Mr. Madison completed his undergraduate degree at the University of Massachusetts.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
SHIELD THERAPEUTICS PLC
0,24% | 31.12.2022 | 1 893 039 ( 0,24% ) | 31 992 $ | 30.04.2024 |
Aktive Positionen von Gregory Madison
Unternehmen | Position | Beginn |
---|---|---|
SHIELD THERAPEUTICS PLC | Vorstandsvorsitzender | 01.06.2021 |
Kidney Care Partners
Kidney Care Partners Medical/Nursing ServicesHealth Services Kidney Care Partners provides healthcare services. It specializes in patient survival, hospitalization and patient experience with care. The company was founded in May 2003 and is headquartered in Washington, DC. | Direktor/Vorstandsmitglied | - |
American Kidney Fund, Inc.
American Kidney Fund, Inc. Medical/Nursing ServicesHealth Services The American Kidney Fund provides treatment and financial assistance to patients with chronic kidney disease. It also provides assistance with expenses that insurance will not cover, such as transportation to dialysis, medications, special diet, kidney donor expenses, and other treatments. It also conducts specialty programs that help patients afford treatment during emergency travel and recover from natural disasters. The company was founded in 1971, and is headquartered in Rockville, MD. | Direktor/Vorstandsmitglied | - |
Phosphate Therapeutics Ltd.
Phosphate Therapeutics Ltd. BiotechnologyHealth Technology Phosphate Therapeutics Ltd. provides research and experimental development on biotechnology. It engages in development of drug named PT20 to cure high phosphate levels in blood. The company was founded in 2011 and is headquartered in Gateshead Quays, the United Kingdom. | Direktor/Vorstandsmitglied | 18.06.2021 |
Ehemalige bekannte Positionen von Gregory Madison
Unternehmen | Position | Ende |
---|---|---|
KERYX BIOPHARMACEUTICALS | Vorstandsvorsitzender | 30.04.2018 |
AMAG PHARMACEUTICALS, INC. | Corporate Officer/Principal | 07.02.2014 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01.01.2012 |
Melt Pharmaceuticals, Inc.
Melt Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Melt Pharmaceuticals, Inc. engages in the development and commercialization of proprietary non-opioid, non-intravenous, or non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. It intends to seek regulatory approval through the FDA regulatory pathway for the proprietary, patented small-molecule product candidates. The company was founded by Mark L. Baum on April 3, 2018 and is headquartered in Brentwood, TN. | Vorstandsvorsitzender | - |
Ausbildung von Gregory Madison
University of Massachusetts | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
SHIELD THERAPEUTICS PLC | Health Technology |
Private Unternehmen | 7 |
---|---|
AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
Kidney Care Partners
Kidney Care Partners Medical/Nursing ServicesHealth Services Kidney Care Partners provides healthcare services. It specializes in patient survival, hospitalization and patient experience with care. The company was founded in May 2003 and is headquartered in Washington, DC. | Health Services |
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Melt Pharmaceuticals, Inc.
Melt Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Melt Pharmaceuticals, Inc. engages in the development and commercialization of proprietary non-opioid, non-intravenous, or non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. It intends to seek regulatory approval through the FDA regulatory pathway for the proprietary, patented small-molecule product candidates. The company was founded by Mark L. Baum on April 3, 2018 and is headquartered in Brentwood, TN. | Health Technology |
American Kidney Fund, Inc.
American Kidney Fund, Inc. Medical/Nursing ServicesHealth Services The American Kidney Fund provides treatment and financial assistance to patients with chronic kidney disease. It also provides assistance with expenses that insurance will not cover, such as transportation to dialysis, medications, special diet, kidney donor expenses, and other treatments. It also conducts specialty programs that help patients afford treatment during emergency travel and recover from natural disasters. The company was founded in 1971, and is headquartered in Rockville, MD. | Health Services |
Phosphate Therapeutics Ltd.
Phosphate Therapeutics Ltd. BiotechnologyHealth Technology Phosphate Therapeutics Ltd. provides research and experimental development on biotechnology. It engages in development of drug named PT20 to cure high phosphate levels in blood. The company was founded in 2011 and is headquartered in Gateshead Quays, the United Kingdom. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |